Lucia Bio
Lucia Bio is developing highly selective spleen tyrosine kinase (Syk) inhibitors for potential application in peripheral immunology, neurology and haematology/oncology.
Next generation Syk inhibitors targeting a clinically validated node in human disease
Lucia Bio, a collaboration between UniQuest and MTM is the first company in the Brisbane Pod. Lucia Bio is capitalising on QEDDI’s focused discovery and development of oral small molecule inhibitors of Syk, built on the deep knowledge of Syk and dependent pathways.
Potent and selective Syk inhibitor
An extensive portfolio of molecules with tailored drug-like properties for application in peripheral immunology, neurology and haematology/oncology.
International project team
Experienced project team assembled with the goal of moving a Syk inhibitor into formal clinical development.
